Rhenium-188 (Re-188) is a high-energy beta-emitting radionuclide with a 17-hour half-life and a co-emitted 155 keV gamma photon, making it one of the most versatile theranostic isotopes for targeted radionuclide therapy and SPECT-based dosimetry. At Protheragen, we leverage deep expertise in transition-metal radiochemistry to deliver Re-188 radiolabeling services tailored to your molecular targets—from peptides and antibody fragments to small-molecule ligands—accelerating your radiopharmaceutical pipeline from concept to clinic.
Rhenium-188 is produced carrier-free via a tungsten-188/rhenium-188 (188W/188Re) generator system, enabling on-site, on-demand availability without the logistical constraints of reactor-produced isotopes. Its decay profile features high-energy beta particles (Eβ,max = 2.1 MeV) capable of delivering a mean path length of approximately 2.2 mm in tissue, which is particularly advantageous for treating bulky solid tumors or achieving homogeneous dose distribution in heterogeneous lesions. The simultaneous emission of a 155 keV gamma ray (15% abundance) allows real-time SPECT imaging for biodistribution assessment and absorbed dose calculations, establishing Re-188 as a true theranostic radionuclide.
Fig 1. 188Re simplified production and decay scheme. (Uccelli, Licia, et al., 2022)
The radiochemistry of Re-188 presents both opportunities and challenges. As a group 7 transition metal, rhenium shares chemical homology with technetium-99m, allowing established chelation strategies—such as direct reduction-labeling, HYNIC-mediated conjugation, tricarbonyl core ([Re(CO)3]+) coordination, and nitrido-based platforms—to be adapted for Re-188. However, perrhenate ([188Re]ReO4⁻) is more resistant to reduction than pertechnetate, necessitating optimized reducing conditions, carefully selected bifunctional chelators (BCAs), and rigorous quality control to achieve high radiochemical purity (>95%), excellent in vitro stability, and preserved biological activity of the labeled vector. These factors underscore the critical importance of specialized radiochemistry expertise in Re-188 conjugate development.
Protheragen is a specialized radiopharmaceutical CRDMO and CRO offering end-to-end support for preclinical research and Investigator-Initiated Trial (IIT) clinical studies. Our Re-188 radiolabeling platform integrates advanced generator chemistry, validated chelation methodologies, and comprehensive analytical characterization to produce radioconjugates with consistent batch-to-batch quality. Whether you are developing peptide receptor radionuclide therapy (PRRT) agents, radioimmunotherapy constructs, or novel small-molecule radioligands, our multidisciplinary team—spanning radiochemists, pharmacologists, and regulatory specialists—ensures that your Re-188 program advances efficiently from early proof-of-concept to regulatory-ready clinical material.
We design and execute Re-188 labeling strategies for peptides, peptidomimetics, and small-molecule ligands targeting receptors such as PSMA, FAP, SSTR, and integrins. Our approach includes chelator selection (e.g., DOTA, NODAGA, HYNIC, or tricarbonyl precursors), radiolabeling optimization, and purification to achieve high specific activity and radiochemical purity.
We provide direct and indirect radiolabeling of monoclonal antibodies, antibody fragments (Fab, scFv), and engineered scaffold proteins with Re-188. Methods include thiol-reduction direct labeling, prelabeling of activated bifunctional chelators, and post-conjugation radiometalation, with full immunoreactivity retention assessment.
We conduct comprehensive in vitro stability profiling (human serum, PBS, challenge with DTPA/histidine), lipophilicity determination (logD), plasma protein binding assays, and cell-based binding/internalization studies to validate the integrity and targeting fidelity of your Re-188 radioconjugate.
Our preclinical team performs in vivo biodistribution, SPECT/CT imaging, and dosimetry calculations in rodent and large-animal models. We quantify tumor uptake, normal-organ clearance kinetics, and therapeutic efficacy to generate data packages supporting IND-enabling studies and IIT protocol design.
Our Re-188 radiolabeling workflow is structured to ensure reproducibility, regulatory compliance, and rapid turnaround. Each project begins with a detailed consultation to define the target vector, intended application, and quality specifications, followed by systematic execution across five integrated stages:
Step 1: Project Consultation & Feasibility Assessment — We evaluate your targeting molecule (peptide, antibody, or small molecule) for Re-188 compatibility, recommend optimal chelation chemistry (direct reduction, HYNIC, tricarbonyl, or nitrido), and establish project milestones, deliverables, and regulatory pathways.
Step 2: Chelator Synthesis & Bioconjugate Preparation — If indirect labeling is selected, we synthesize or procure the bifunctional chelator, conjugate it to your vector under controlled conditions, and confirm conjugation efficiency by mass spectrometry, HPLC, or UV-Vis spectroscopy.
Step 3: Re-188 Generator Elution & Radiolabeling — Perrhenate is eluted from the W-188/Re-188 generator, chemically reduced (typically with stannous chloride, tricarbonyl kit, or other validated reductants), and reacted with the chelator-vector conjugate or directly with the reduced biomolecule under optimized pH, temperature, and time parameters.
Step 4: Purification & Comprehensive Quality Control — The crude reaction mixture is purified by size-exclusion chromatography, solid-phase extraction, or HPLC. We then perform radiochemical purity analysis (ITLC/HPLC), radionuclidic identity verification, specific activity calculation, and in vitro stability testing to confirm product integrity.
Step 5: Stability Validation & Preclinical Characterization — Final products undergo in vivo biodistribution and SPECT imaging in validated animal models, alongside extended in vitro stability monitoring, to generate a complete preclinical data package.
Ready to advance your Re-188 radiopharmaceutical program? Reach out to us today to discuss your project requirements, receive a tailored proposal, and discover how Protheragen's integrated radiochemistry and preclinical capabilities can accelerate your path from bench to bedside. Our team is standing by to contact you with a customized development strategy designed around your molecular target and clinical objectives.
Reference